e-Zassi software streamlines commercialisation of medical device technologies

7 May 2009

e-Zassi.com is predictive decision support software that provides rapid due diligence, triaging and assessment of new medical device innovations.

Preliminary due diligence and development of new medical device technologies can cost up to $75,000 and take up to three months. Now e-Zassi.com gives innovators, device manufacturers, service providers, venture capital firms, researchers, healthcare providers and others access to a new online membership community with software that shortens this process to about 90 minutes for only a few thousand dollars.

According to e-Zassi Chief Executive Officer Peter M. von Dyck: “Not knowing critical details can dramatically hinder a technology from being successfully funded, licensed, developed or commercialized.”

These critical details, says von Dyck, include: a new technology’s probable regulatory classifications; the associated clinical endpoints to support the safety and marketing claims to earn market clearances; early stage clarity on the reimbursement and market landscape; and identification of material manufacturing, distribution and sales burdens.

e-Zassi.com members can extract critical technical and business-related traits and attributes for a deep analysis and forecast of the opportunities and potential challenges that may be encountered from time of invention throughout all development and commercialization phases.

Development and commercially related outputs that are critical include: technology transfer; business development; market and commercial analysis; due diligence and portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants.

All e-Zassi online elements are uniquely categorized and organized among thousands of Device Network Attributes (DNA) the company identified over several years.

“We now know how this business and technology ‘DNA’ can be leveraged by the members in the e-Zassi community to rapidly identify synergistic partners and technological opportunities,” says von Dyck. “Empowering our members to leverage these vital attributes on a private online community materially enhances search/match relevancy on a level not available on any other existing network, which helps lower costs, save time and enhance success rates.”

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. e-Zassi software streamlines commercialisation of medical device technologies 7 May 2009 e-Zassi.com is predictive decision support software that provides rapid due diligence, triaging and assessment of new medical device innovations. Preliminary due diligence and development of new medical device technologies can cost up to $75,000 and take up to three months. Now e-Zassi.com gives innovators, device manufacturers, service providers, venture capital firms, researchers, healthcare providers and others access to a new online membership community with software that shortens this process to about 90 minutes for only a few thousand dollars. According to e-Zassi Chief Executive Officer Peter M. von Dyck: “Not knowing critical details can dramatically hinder a technology from being successfully funded, licensed, developed or commercialized.” These critical details, says von Dyck, include: a new technology’s probable regulatory classifications; the associated clinical endpoints to support the safety and marketing claims to earn market clearances; early stage clarity on the reimbursement and market landscape; and identification of material manufacturing, distribution and sales burdens. e-Zassi.com members can extract critical technical and business-related traits and attributes for a deep analysis and forecast of the opportunities and potential challenges that may be encountered from time of invention throughout all development and commercialization phases. Development and commercially related outputs that are critical include: technology transfer; business development; market and commercial analysis; due diligence and portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants. All e-Zassi online elements are uniquely categorized and organized among thousands of Device Network Attributes (DNA) the company identified over several years. “We now know how this business and technology ‘DNA’ can be leveraged by the members in the e-Zassi community to rapidly identify synergistic partners and technological opportunities,” says von Dyck. “Empowering our members to leverage these vital attributes on a private online community materially enhances search/match relevancy on a level not available on any other existing network, which helps lower costs, save time and enhance success rates.” Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.